Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: limit who wrote (328)	7/9/1999 11:07:00 PM
From: Walkingshadow	Read Replies (1) \| Respond to of 3044

Here's a fairly comprehensive (but quite readable) article on MLNM and others' work on obesity genes and weight control in general, which appeared in Chemical and Engineering News a couple of weeks ago: pubs.acs.org Note the table in the article, which shows a total of ELEVEN potential targets at which to direct weight control drug candidate strategies. Although MLNM/s discovery of mahogany recently appears to me to be a significant advance, it would nevertheless hardly seem a foregone conclusion that MLNM has an open, undencumbered field ahead of it in the development of weight control products. Some of these (notably, Leptin [AMGN]) are in clinical trials. My point is that we are very early in this game and there are many possible outcomes, so it would behoove one to pay close attention to developments here. (Disclosure: I'm long MLNM [among others]) As always, JMVHO.... Walkingshadow